A Study of LY3041658 in Participants With Skin Diseases

Completed · Phase 1 · Has a placebo group

Conditions studied: Skin Diseases, Psoriasis

In brief

The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

Key facts

Study ID

NCT02896868

Run by

Eli Lilly and Company

People needed

60

Starts

2016-11-08

Expected to finish

2019-03-19

Last updated by the study team

2019-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Investigator confirmed diagnosis of certain skin diseases for at least 6 months.
• Active skin lesions that are not responding to standard therapies.
• Willing to undergo pre- and post-treatment skin biopsies of lesions.

You may not qualify if…

• Have other skin diseases that may interfere with evaluation of the specified skin disease being studied.

Where it is running

• Parexel Early Phase Unit at Glendale — Glendale, California, United States
• Dawes Fretzin Clinical Research — Indianapolis, Indiana, United States
• PAREXEL-Phase 1 Baltimore Harbor Hospital Center — Baltimore, Maryland, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.